LB-OR-4 Ligand-Bound Thyroid Hormone Receptor Contributes to Reprogramming of Pancreatic Acinar Cells

Program: Late-Breaking Abstracts
Session: LB-OR-Late-Breaking Oral Session
Saturday, June 15, 2013: 11:30 AM-1:00 PM
Presentation Start Time: 12:15 PM
Room 122 (Moscone Center)
Fumihiko Furuya*, Hiroki Shimura, Sayaka Ichijo, Masashi Ichijo and Tetsuro Kobayashi
University of Yamanashi, Chuo, Yamanashi, Japan
One goal of diabetic regenerative medicine is to instructively convert mature pancreatic exocrine cells into insulin-producing cells. We recently reported that ligand-bound thyroid hormone receptor α (TRα) plays a critical role in expansion of the β-cell mass during postnatal development. Herein, we used adenovirus vector that expresses TRα driven by the amylase 2 promoter (AdAmy2TRα) to induce the reprogramming of pancreatic acinar cells into insulin-producing cells. Treatment with L-3,5,3-triiodothyronine  increases the association of TRα with the p85α subunit of Phosphatidylinositol 3-Kinase (PI3K), leading to the phosphorylation and activation of Akt and the expression of Pdx1, Ngn3 and MafA in purified acinar cells. Analyses performed with the lectin-associated cell lineage tracing system and the Cre/loxP-based direct cell lineage tracing system indicate that newly synthesized insulin-producing cells originate from elastase-expressing pancreatic acinar cells. Insulin-containing secretory granules were identified in these cells by electron microscopy. The inhibition of p85α expression by siRNA or the inhibition of PI3K by LY294002 prevents the expression of Pdx1, Ngn3 and MafA and the reprogramming to insulin-producing cells. In immunodeficient mice with streptozotocin-induced hyperglycemia, treatment with AdAmy2TRα leads to the reprogramming of pancreatic acinar cells to insulin-producing cells in vivo. Our findings suggest that ligand-bound TRα plays a critical role in β-cell regeneration during postnatal development via activation of PI3K signaling.

Nothing to Disclose: FF, HS, SI, MI, TK

*Please take note of The Endocrine Society's News Embargo Policy at